0.9 USD
-0.01 (-0.96%)
0.8624 USD
-0.04 (-4.18%)
Overall KTTA gets a fundamental rating of 0 out of 10. We evaluated KTTA against 525 industry peers in the Biotechnology industry. KTTA may be in some trouble as it scores bad on both profitability and health. KTTA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past 5 years KTTA always reported negative net income.
- KTTA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The profitability ratios for KTTA are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- KTTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- KTTA has more shares outstanding than it did 1 year ago.
- There is no outstanding debt for KTTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for KTTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PASITHEA THERAPEUTICS CORP / KTTA FAQ
What is the fundamental rating for KTTA stock?
ChartMill assigns a fundamental rating of 0 / 10 to KTTA.
What is the valuation status of PASITHEA THERAPEUTICS CORP (KTTA) stock?
ChartMill assigns a valuation rating of 0 / 10 to PASITHEA THERAPEUTICS CORP (KTTA). This can be considered as Overvalued.
What is the profitability of KTTA stock?
PASITHEA THERAPEUTICS CORP (KTTA) has a profitability rating of 0 / 10.
What is the financial health of PASITHEA THERAPEUTICS CORP (KTTA) stock?
The financial health rating of PASITHEA THERAPEUTICS CORP (KTTA) is 0 / 10.